Health Care · Surgical & Medical Instruments & Apparatus

DXCM Dexcom SEC Filings & Insider Trading Activity 2026

company
CIK 1093557117 filings
Nasdaq 100
S&P 500

DXCM at a glance

Dexcom (DXCM, SEC CIK 1093557) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Dexcom (DXCM) reported revenue of $4.7 billion (up 15.6% from FY2024) and net income of $836.3 million. Diluted EPS was $2.09.
  • As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Dexcom (DXCM) shares worth $14.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Brown Michael Jon on November 16, 2026 of 1,700 shares at $83.46 per share.
  • In the last 90 days, DXCM insiders reported 0 open-market purchases ($0) and 9 open-market sales ($2.1M) on Form 4, a net sale of $2.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$4.7B
+15.6% vs prior year
Insiders · 90 days
0 buys · 9 sells
Net −$2.1M
13F holders
38 funds
$14.8B · −1 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 8.01 · Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management
  • New product launched: Stelo, first over-the-counter glucose biosensor for prediabetes and Type 2 diabetes adults not using insulin (U.S. launch Aug 2024)
  • Strategic shift: Expanded market beyond insulin-using diabetics to prediabetes and broader metabolic health with OTC Stelo product
  • Quantitative metric: G7 15 Day system FDA cleared with 15.5-day wear, 8.0% MARD accuracy, coverage by Medicare and Medicaid in majority of U.S. states
  • Noteworthy fact: Dexcom ONE+ CGM system received CE Mark approval Nov 2023 and launched in multiple European countries, expanding international presence

Management Discussion & Analysis

  • Revenue $4,662M, up 16% YoY from $4,033M driven by 600K-700K net customer additions
  • Operating margin 20.0% vs 14.9%, operating income $911.8M up 52% YoY from $600.0M
  • Best segment: U.S. distributor revenue $3,195.7M up $371.3M; worst segment: U.S. direct revenue $139.2M up $73.8M (smallest absolute growth)
  • Net income $836.3M up 45% YoY with net margin 17.9% vs 14.3%
  • Cash from operations supporting R&D ($599.1M), SG&A ($1,291M), no specific buybacks/dividends noted; expectations of adequate liquidity, possible future debt market access for inorganic growth

Risk Factors

  • Cybersecurity risk exposure due to integration of cloud-based technology platforms increasing operational costs
  • Board Technology Committee delegation for cybersecurity risk oversight with annual compliance reviews to applicable laws and standards
  • Key-person dependency on cybersecurity officers with 15-25 years experience and multiple professional certifications managing risk
  • Supply chain vulnerability linked to global IT infrastructure managed by CIO with 30 years experience in IT and supply chain
  • No specific regulatory, geopolitical, competitive, or financial risk detailed in this section

AI summary of the DXCM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New shareholder-return risk: October 2026 authorization of $1.00 billion 2027 Share Repurchase Program
  • Most material update: Repurchases may not enhance share price or earnings per share
  • Market risk: Repurchase timing could expose Dexcom to unfavorable market conditions and price volatility
  • Financial risk: Share buybacks depend on availability of funds and competing strategic opportunities

Management Discussion & Analysis

  • Revenue $1,344.5M, up $135.2M or 11% YoY, driven by disposable sensor volume
  • Gross margin 64.3% vs 60.5% YoY, supported by G7 15 Day and manufacturing efficiencies
  • Operating income $327.2M, up 35% YoY; operating margin 24.3% vs 20.1%
  • Cash $1.82B, down $180.8M from December 31, 2025; nine-month operating cash flow $1.12B
  • Share repurchases drove $1,023.8M financing cash use; significant manufacturing capital expenditures expected next year

AI summary of the DXCM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item 8.01: Other Events

  • Board authorized up to $1.0 billion in common-stock repurchases through December 31, 2027
  • Potential shareholder return and share-count reduction, but no guaranteed repurchase amount

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1.344B, up 11% YoY, with U.S. growth 14% versus international growth 5%
  • GAAP operating margin 24.3%, up 420 basis points, signaling strong operating leverage

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026 announced
  • Investor focus: revenue, profitability, guidance and operating metrics in Exhibit 99.1
Filed Sep 14, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Dexcom announced Mr. Sylvain’s promotion on September 14, 2026
  • Promotion details and leadership implications appear in Exhibit 99.1 accompanying the filing

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CFO Jereme Sylvain promoted to EVP, Chief Operating Officer and CFO, effective September 14, 2026
  • Expanded mandate combines financial leadership with operational oversight
Filed Sep 10, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded to 13 directors with immediate appointment of Glenn S. Boehnlein through the 2027 annual meeting
  • Independent director adds oversight to Operations & Innovation and Audit committees

Item 7.01: Regulation FD Disclosure

  • Dexcom appointed Mr. Boehnlein to its Board, signaling a governance and strategic leadership change
  • Appointment details and rationale are contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Glenn Boehnlein appointed independent director effective September 10, 2026
  • Former Stryker CFO brings 20+ years of MedTech finance and operating experience

AI summaries of DXCM 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DXCM

Don't miss the next DXCM filing

  • Alerts as it files. A push when DXCM files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DXCM, by share count.
  • Ask anything. An AI agent that reads every DXCM filing and answers with sources.

DXCM alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Brown Michael JonSellNov 16, 2026$83.46
Sylvain Jereme MFNov 8, 2026$79.41
Leach Jacob StevenFNov 8, 2026$79.41
Brown Michael JonFNov 8, 2026$79.41
Stern SadieFNov 8, 2026$79.41
Ashley Euan A.GOct 30, 2026-
Stern SadieSellOct 27, 2026$78.62
Brown Michael JonSellOct 15, 2026$85.48

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$4.0B$4.7B
Gross Profit-$2.4B$2.8B
Operating Income-$600.0M$911.8M
Net Income-$576.2M$836.3M
Gross Margin-60.5%60.1%
Op. Margin-14.9%19.6%
Net Margin-14.3%17.9%
Balance Sheet
Total Assets$6.3B$6.5B$6.3B
Equity$2.1B$2.1B$2.7B
ROE-27.4%30.5%
Per Share
EPS-$1.42$2.09
Cash Flow
Operating CF-$989.5M$1.4B
CapEx-$358.8M$363.5M

Source: XBRL data in Dexcom (DXCM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate DXCM share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
DXCM shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202638$14.84B
Q2 202639$11.18B
Q1 202636$10.28B
Q4 202537$11.45B
Q3 202538$11.71B
Q2 202536$13.89B
Q1 202534$8.15B
Q4 202430$8.32B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 288 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

DXCM filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 3, 2026--
8-KOct 29, 2026Analysis-
10-QOct 29, 2026Analysis
4Oct 28, 2026--
4Oct 19, 2026--
4Sep 30, 2026--
4Sep 16, 2026--
4Sep 16, 2026--
4Sep 14, 2026--
8-KSep 14, 2026Analysis-
8-KSep 10, 2026Analysis-
4Sep 10, 2026--
4Aug 28, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 24, 2026--
4Aug 17, 2026--
4Aug 13, 2026--

Related Health Care companies

All Health Care →

DXCM SEC filings: frequently asked questions

Are DXCM insiders buying or selling?

In the last 90 days, Dexcom (DXCM) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $2.1 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold DXCM stock?

As of September 30, 2026, the largest Dexcom (DXCM) holders among the 13F filers tracked by SignalX were BlackRock ($3.3 billion), Vanguard Capital Management LLC ($2.1 billion), Vanguard Portfolio Management LLC ($1.7 billion), State Street Corp ($1.6 billion), Invesco Ltd ($1.4 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was DXCM's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Dexcom (DXCM) reported revenue of $4.7 billion (up 15.6% from FY2024) and net income of $836.3 million. Diluted EPS was $2.09. The figures come from the XBRL data in the 10-K.

What are the main risks in DXCM's latest 10-K?

In the 10-K filed February 12, 2026, Dexcom (DXCM) flagged: Cybersecurity risk exposure due to integration of cloud-based technology platforms increasing operational costs. Board Technology Committee delegation for cybersecurity risk oversight with annual compliance reviews to applicable laws and standards. (AI summary of the Risk Factors section.)

What did DXCM report in its latest 8-K?

Dexcom (DXCM) filed an 8-K on October 29, 2026 reporting Item 8.01 (Other Events) and Item 2.02 (Results of Operations and Financial Condition). Board authorized up to $1.0 billion in common-stock repurchases through December 31, 2027.

What are the latest DXCM SEC filings?

Dexcom (DXCM) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 18, 2026.

What is DXCM's SEC CIK number?

Dexcom (DXCM)'s SEC Central Index Key (CIK) is 1093557. EDGAR lists every DXCM filing under that number.

Ask anything about DXCM

The research agent reads DXCM's filings, financials, insider trades and 13F holders, then answers with sources.